EUROPEAN JOURNAL OF
PHARMACEUTICAL AND MEDICAL RESEARCH

( An ISO 9001:2015 Certified International Journal )

An International Peer Reviewed Journal for Pharmaceutical, Medical & Biological Sciences

An Official Publication of Society for Advance Healthcare Research (Reg. No. : 01/01/01/31674/16)

European Journal of Pharmaceutical and Medical Research (EJPMR) has indexed with various reputed international bodies like : Google Scholar , Indian Science Publications , InfoBase Index (In Process) , SOCOLAR, China , Research Bible, Fuchu, Tokyo. JAPAN , International Society for Research activity (ISRA) , Scientific Indexing Services (SIS) , Polish Scholarly Bibliography , Global Impact Factor (GIF) (Under Process) , Universal Impact Factor , International Scientific Indexing (ISI), UAE , Index Copernicus , CAS (A Division of American Chemical Society) USA (Under Process) , Directory of Open Access Journal (DOAJ, Sweden, in process) , UDLedge Science Citation Index , CiteFactor , Directory Of Research Journal Indexing (DRJI) , Indian citation Index (ICI) , Journal Index (JI, Under Process) , Directory of abstract indexing for Journals (DAIJ) , Open Access Journals (Under Process) , Impact Factor Services For International Journals (IFSIJ) , Cosmos Impact Factor , Jour Informatics (Under Process) , Eurasian Scientific Journal Index (ESJI) , International Innovative Journal Impact Factor (IIJIF) , Science Library Index, Dubai, United Arab Emirates , Pubmed Database [NLM ID: 101669306] (Under Process) , IP Indexing (IP Value 2.40) , Web of Science Group (Under Process) , Directory of Research Journals Indexing , Scholar Article Journal Index (SAJI) , International Scientific Indexing ( ISI ) , Scope Database ,

ISSN 2394-3211

Impact Factor: 6.222

ICV - 79.57

Abstract

TREATMENT OF VISCERAL LEISHMANIASIS IN INDIAN SUBCONTINENT

Anup Singh*

ABSTRACT

The treatment of Visceral leishmaniasis has been challenging because of scarcity in treatment options. Long treatment regimens and associated adverse effects further makes its treatment arduous. The present treatment guidelines in Indian subcontinent includes a single dose of 10 mg/kg of liposomal amphotericin B (L-AmB) or combination therapy consisting of multidrug therapy (L-AmB + miltefosine, L-AmB + paromomycin (PM), or miltefosine + PM). With the emergence of drug resistance there is need of development of new drugs with anti-leishmanial activity to achieve the goal of VL Elimination programme in Indian subcontinent.

Keywords: kala-azar, liposomal amphotericin B, miltefosine, paromomycin.

[Full Text Article]

SJIF Impact Factor: 6.222

INDEXING

Indexing

LOGIN

NEWS & UPDATION

New Issue Published
Its Our pleasure to inform you that, EJPMR 1 May 2023 Issue has been Published, Kindly check it on https://www.ejpmr.com/issue

EJPMR: MAY ISSUE PUBLISHED
MAY issue has been successfully launched on 1 MAY 2023.

EJPMR New Impact Factor
Its our Pleasure to Inform you that EJPMR Impact Factor has been increased from 5.804 to 6.222, due to high quality Publication at International Level